Author:
Zhuang Tony Zibo,Harik Lara,Force Seth,Hadadi Agreen,Bilen Mehmet Asim,Brown Jacqueline T.,Carthon Bradley C.,Goldman Jamie,Kucuk Omer,Master Viraj A.,Nazha Bassel
Abstract
The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors.